Targeting the FAPα/Integrin αvβ1 complex attenuates hepatic stellate cell activation and liver fibrosis
Chun Guan, Nuo Cheng, Yu Tong, Yifei Li, Jiayi Liu, Haishan Luo, Shihao Liu, Jihai Chen, Cong Wang
Journal:BIOCHEMICAL PHARMACOLOGY
IF:6.5
DOI:10.1016/j.bcp.2026.117801
PMID:41687828
Published:2026-02-11
research field:分子生物学药物开发肝脏病学细胞信号转导纤维化研究
Abstract
Hepatic stellate cell (HSC) activation is central to liver fibrosis. Fibroblast activation protein α (FAPα) is highly expressed in activated HSCs, yet its regulatory role remains unclear. This study investigates the function and mechanism of FAPα in HSC activation and fibrosis progression. Using TGF-β1-induced LX2 cells and CCl 4 -induced mouse models, along with small-molecule inhibitors and multi-omics analyses, we found that inhibiting FAPα suppressed HSC activation, proliferation, migration, and ameliorated fibrosis. Notably, FAPα formed a functional complex with Integrin αvβ1 in activated HSCs. Dual inhibition of FAPα/Integrin αvβ1 more effectively attenuated HSC activation and fibrosis than single-agent treatment. Transcriptomic and proteomic studies revealed that the complex acts through the GPC3/FGF21 axis. This study identifies the FAPα/Integrin αvβ1 complex as a key regulator of liver fibrosis and provides a novel combinatory therapeutic strategy for anti-fibrotic drug development.
本文使用的Yeasen产品


